Goldman Sachs
DGX icon

Goldman Sachs’s Quest Diagnostics DGX Stock Holding History

Goldman Sachs’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,000
Closed -$4.69M – 6597
2025
Q4 		$4.69M Buy
+27,000
New +$4.92M ﹤0.01% 3809
2018
Q4 		– Sell
-39,000
Closed -$4.21M – 5310
2018
Q3 		$4.21M Buy
+39,000
New +$4.28M ﹤0.01% 3111
2018
Q2 		– Sell
-200
Closed -$20K – 5726
2018
Q1 		$20K Sell
200
-24,500
-99% -$2.51M ﹤0.01% 5672
2017
Q4 		$2.43M Buy
24,700
+10,600
+75% +$1M ﹤0.01% 3618
2017
Q3 		$1.32M Buy
14,100
+13,200
+1,467% +$1.4M ﹤0.01% 4343
2017
Q2 		$100K Sell
900
-2,800
-76% -$296K ﹤0.01% 6118
2017
Q1 		$363K Sell
3,700
-3,100
-46% -$296K ﹤0.01% 5301
2016
Q4 		$625K Sell
6,800
-200
-3% -$17.2K ﹤0.01% 4861
2016
Q3 		$592K Sell
7,000
-700
-9% -$58.8K ﹤0.01% 4885
2016
Q2 		$627K Sell
7,700
-73,800
-91% -$5.62M ﹤0.01% 4637
2016
Q1 		$5.82M Buy
81,500
+74,400
+1,048% +$4.99M ﹤0.01% 2613
2015
Q4 		$505K Sell
7,100
-134,200
-95% -$9.02M ﹤0.01% 4914
2015
Q3 		$8.69M Buy
141,300
+131,400
+1,327% +$9.18M ﹤0.01% 2367
2015
Q2 		$718K Sell
9,900
-11,400
-54% -$842K ﹤0.01% 4855
2015
Q1 		$1.64M Sell
21,300
-24,700
-54% -$1.77M ﹤0.01% 3978
2014
Q4 		$3.08M Sell
46,000
-28,600
-38% -$1.8M ﹤0.01% 3429
2014
Q3 		$4.53M Sell
74,600
-352,700
-83% -$21.7M ﹤0.01% 3117
2014
Q2 		$25.1M Buy
427,300
+291,700
+215% +$17.1M 0.01% 1621
2014
Q1 		$7.85M Sell
135,600
-133,500
-50% -$7.16M ﹤0.01% 2572
2013
Q4 		$14.4M Sell
269,100
-39,300
-13% -$2.33M ﹤0.01% 2029
2013
Q3 		$19.1M Buy
308,400
+221,400
+254% +$13.3M 0.01% 1662
2013
Q2 		$5.28M Buy
+87,000
New +$5.18M ﹤0.01% 2683

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Goldman Sachs's DGX Position: Q1 2026 in Review

Goldman Sachs reduced its Quest Diagnostics (DGX) stake by 21% in Q1 2026, selling an estimated $70M and leaving 1,348,694 shares worth $264M. The position accounts for 0.03% of the portfolio, ranked #547.

Goldman Sachs first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $297M in Q4 2025. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Goldman Sachs held 1,348,694 shares of Quest Diagnostics worth $264M as of Q1 2026.
  • Goldman Sachs sold 360,231 Quest Diagnostics shares in Q1 2026, an estimated $70M.
  • Quest Diagnostics made up 0.03% of Goldman Sachs's portfolio in Q1 2026, its #547 holding.
  • Goldman Sachs first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Quest Diagnostics position peaked at $297M in Q4 2025.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.